Pharma BD Deal Intelligence

Gilead Sciences Inc. / Pharmasset Inc.

2011 · Acquisition/Merger · $11.2B · Complete

Announcement Sentiment

58

Neutral / mixed

Outcome Score

98

Worked — the deal delivered on its rationale.

Gilead Sciences acquired Pharmasset for $11.2 billion in cash, gaining sofosbuvir (PSI-7977), a nucleotide analog for hepatitis C treatment.

Key facts

Announced Nov 21, 2011
Closed Jan 11, 2012
Deal value $11.2B
Deal type Acquisition/Merger
Therapeutic area Infectious Disease
Indications Hepatitis C
Key assets sofosbuvir (PSI-7977), PSI-938
Mechanism Nucleotide analog NS5B polymerase inhibitor

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals